Disarm Therapeutics is creating breakthrough disease-modifying therapeutics to treat patients with neurological diseases by preventing axonal degeneration.
Axonal degeneration is a common yet unaddressed pathology in a broad range of chronic and acute diseases of the central, ocular, and peripheral nervous systems.
Our scientific founders have identified SARM1 as the central driver of axonal degeneration, which causes severe sensory, motor, and cognitive symptoms and disease progression.
Disarm is developing SARM1 inhibitors to directly prevent the loss of axons, providing a breakthrough treatment approach for patients with severe neurological diseases including multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies.
Disarm was founded in 2016 by Dr. Jeffrey Milbrandt and Dr. Aaron DiAntonio of Washington University in St. Louis, Atlas Venture, and a team of exceptional scientists and drug developers.
Jeffrey Milbrandt, MD, PhD, co-chair
Chair, Department of Genetics, James S. McDonnell Professor of Genetics, Pathology and Immunology, Medicine, and Neurology, Washington University; founder, Disarm
Peter Calabresi, MD
Professor of Neurology and Neuroscience, Director of the Multiple Sclerosis Center, and Director, Division of Neuroimmunology and Neurological Infections, Johns Hopkins University
Robert Copeland, PhD
President, CSO, and founder, Accent Therapeutics
Ahmet Hoke MD, PhD
Professor of Neurology and Neuroscience, Director of the Neuromuscular Division, Johns Hopkins University, School of Medicine
Douglas Kerr, MD, PhD, MBA
Head of Preclinical Research and Clinical Development, Generation Bio
Aaron DiAntonio, MD, PhD, co-chair
Alan A. and Edith L. Wolff Professor of Developmental Biology, Washington University; founder, Disarm